A detailed history of Atria Investments LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Atria Investments LLC holds 3,587 shares of EXAS stock, worth $201,051. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,587
Holding current value
$201,051
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$42.43 - $70.83 $152,196 - $254,067
3,587 New
3,587 $244,000
Q4 2023

Feb 14, 2024

BUY
$59.06 - $75.72 $7,736 - $9,919
131 Added 0.69%
19,068 $1.41 Million
Q3 2023

Nov 07, 2023

BUY
$65.94 - $99.04 $44,971 - $67,545
682 Added 3.74%
18,937 $1.29 Million
Q2 2023

Aug 04, 2023

BUY
$62.68 - $95.05 $211,168 - $320,223
3,369 Added 22.63%
18,255 $1.71 Million
Q1 2023

May 10, 2023

BUY
$47.19 - $70.77 $702,470 - $1.05 Million
14,886 New
14,886 $1.01 Million
Q4 2021

Feb 04, 2022

SELL
$72.5 - $100.68 $830,052 - $1.15 Million
-11,449 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$90.24 - $124.05 $269,817 - $370,909
2,990 Added 35.35%
11,449 $1.09 Million
Q2 2021

Aug 10, 2021

BUY
$93.66 - $139.27 $42,053 - $62,532
449 Added 5.61%
8,459 $1.05 Million
Q1 2021

May 11, 2021

SELL
$116.57 - $155.01 $5,595 - $7,440
-48 Reduced 0.6%
8,010 $1.06 Million
Q4 2020

Feb 12, 2021

BUY
$99.61 - $142.12 $802,657 - $1.15 Million
8,058 New
8,058 $1.07 Million
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $213,339 - $587,892
-5,629 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$77.66 - $99.74 $241,755 - $310,490
3,113 Added 123.73%
5,629 $521,000
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $10,211 - $13,841
113 Added 4.7%
2,516 $227,000
Q2 2019

Aug 26, 2019

BUY
$89.51 - $118.04 $215,092 - $283,650
2,403 New
2,403 $285,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.92B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Atria Investments LLC Portfolio

Follow Atria Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atria Investments LLC with notifications on news.